By Fineline Cube Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced it has submitted a new indication approval filing with China’s National Medical Products Administration (NMPA) for Jaitailai (sacituzumab tirumotecan), its TROP2-targeted antibody drug conjugate (ADC). The company is seeking approval for the drug’s use in first-line patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with Merck & Co.’s pembrolizumab (Keytruda).
Proposed Indication Details
| Parameter | Specification |
|---|---|
| Patient Population | First-line locally advanced or metastatic NSCLC |
| Biomarker Requirements | PD-L1 TPS ≥ 1%, EGFR mutation-negative, ALK-negative |
| Treatment Regimen | Jaitailai + pembrolizumab (anti-PD-1 monoclonal antibody) |
| Regulatory Status | NMPA filing submitted |
| Drug Class | TROP2-targeted antibody drug conjugate (ADC) |
This proposed indication would expand Jaitailai’s utility into the first-line NSCLC setting, representing a significant commercial opportunity given the large patient population and established role of PD-1/PD-L1 inhibitors in this treatment paradigm.
Commercial & Development Context
- Existing Approvals: Jaitailai has already secured four indication approvals in China, demonstrating strong regulatory acceptance and clinical utility
- Global Partnership: In May 2022, Merck, Sharp & Dohme (MSD) entered into a licensing agreement for Jaitailai covering territories outside Greater China, validating the asset’s global potential
- Combination Rationale: The proposed combination leverages complementary mechanisms—TROP2-targeted cytotoxic delivery plus PD-1 pathway blockade—to potentially enhance anti-tumor efficacy
- Market Opportunity: First-line NSCLC represents one of the largest oncology markets globally, with combination therapies increasingly becoming the standard of care
- Competitive Landscape: TROP2 ADCs have emerged as a major class in solid tumor treatment, with several agents demonstrating significant clinical benefit in various indications
Strategic Significance
This filing represents a strategic expansion of Kelun-Biotech’s flagship ADC into a high-value indication with established combination partner Keytruda. Success would position Jaitailai as a key component of first-line NSCLC treatment regimens in China, while further validating the company’s ADC platform capabilities.
The partnership with MSD for ex-China territories suggests potential for global development of this combination approach, should Chinese clinical data demonstrate compelling efficacy and safety.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial opportunities. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, competitive dynamics, and market adoption patterns.-Fineline Info & Tech